Sandoz
| Formerly | Sandoz GmbH |
|---|---|
| Company type | Public (Aktiengesellschaft) |
| ISIN | CH1243598427 |
| Industry |
|
| Predecessor | Ciba-Geigy |
| Founded | 1886 |
| Founder |
|
| Headquarters | , |
Key people | |
| Revenue | US$9.647 billion (2023) |
| US$375 million (2023) | |
| US$953 million (2023) | |
| Total assets | US$19.430 billion (2023) |
| Total equity | US$8.654 billion (2023) |
Number of employees | 23,848 (2023) |
| Website | sandoz |
| Footnotes / references | |
Sandoz Group AG is a Swiss company that focuses on generic pharmaceuticals and biosimilars. Prior to October 2023, it was part of a division of Novartis that was established in 2003, when Novartis united all of its generics businesses under the name Sandoz. Before this, the company existed as an independent pharmaceutical manufacturer until 1996, when it was merged with Ciba-Geigy to form Novartis. Prior to the merger, it specialized in medicines used in organ transplants, such as Sandimmune, and various antipsychotics and migraine medicines. Its headquarters were in Holzkirchen, Germany and after the spin-off from Novartis, the headquarters moved to Basel, Switzerland, with most of global functions operating from Holzkichen in Germany, Prague in Czechia, and Barcelona in Spain. Sandoz is the global leader in generic pharmaceuticals and biosimilars.